Caitlin Raymond on Platelet Refractoriness: New Series Alert!
Caitlin Raymond, a board-certified Clinical Pathologist and current Transfusion Medicine Fellow at the National Institutes of Health, shared on LinkedIn:
“New Blog Post: Platelet Refractoriness — An Overview
One of the most frustrating challenges in transfusion medicine is when platelet transfusions don’t “stick.”
Platelet refractoriness is common, multifactorial, and has huge implications for bleeding risk, patient outcomes, and stewardship of scarce blood products.
In this post, I walk through:
- How we define and measure refractoriness (CCI)
- Why non-immune causes (like sepsis, bleeding, or splenomegaly) are the most common and should be ruled out first
- How we evaluate immune causes with HLA typing, antibody screens, PRA, and crossmatches
- Practical management strategies, from HLA-compatible platelets to PRA-guided selection
- The real-world challenges of balancing ideal care with limited resources
Key takeaway: Refractoriness isn’t rare—and a structured approach can make transfusion both safer for patients and more sustainable for the blood supply.”
Read the full post here.
More from Caitlin Raymond featured in HT!
More series on coagulation featured in Hemostasis Today.
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK
-
May 26, 2026, 16:40Hamed Helisaz: Machine Learning for Detecting Missing Heart Medications
-
May 26, 2026, 15:32Haroun Gajraj: Brown Marks After Microsclerotherapy – What Every Practitioner Needs to Know
-
May 26, 2026, 15:29Jacqueline van Paassen: Lack of Essential Clinical Data in DOAC Prescriptions in Community Pharmacies
-
May 26, 2026, 15:22Shazmah Shaikh: One Visual Guide to Understand All Major Anticoagulants
-
May 26, 2026, 14:39Chidinma Favour։ Welcome to Day 25 of My 31-Day Stroke Awareness Series
-
May 26, 2026, 14:35Novel Insights Into Congenital and Acquired Coagulopathies – ICHCC
-
May 26, 2026, 14:24Fernanda Orsi: The Growing Impact of Hematology Research in Latin America
-
May 26, 2026, 14:23Rense Buijvoets: What If Clots Could Be Treated Exactly Where They Form?